Clinigen Joins Decentralized Trials & Research Alliance (DTRA)
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical Products and Services company, is pleased to announce it has joined the Decentralized Trials and Research Alliance (DTRA).
The DTRA consists of an alliance of life sciences and healthcare companies that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. Launched in December 2020, the DTRA seeks to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
It is estimated that clinical trials may be set back by several years in the context of COVID-19, due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators.
Peter Belden, Executive Vice President Services Division, Clinigen, said:
“The COVID-19 pandemic has highlighted why driving change in clinical research is critical. There is an increasing need to ensure we have a model that puts patients at the heart of how trials are designed and run; this is directly linked to our mission of ensuring the right medicine gets to the right patient at the right time. We are proud to be part of the DTRA and look forward to collaborating to drive positive change.”
Craig Lipset, DTRA co-convenor, said:
"Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, Clinigen is demonstrating its leadership to drive change. We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”
Clinigen Group plc
Peter Belden, EVP Services Division
Tel: +44 (0) 1283 495010
Melanie Toyne-Sewell / Tim Linacre / Rozi Morris / Phillip Marriage
Tel: +44 (0) 20 7457 2020
DTRA Media Contact:
Lazar - Finn Partners
Tel: +1 646 871 8485
For non-media inquiries:
Tel: +1 619-209-7371
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,250 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit http://www.clinigen.com
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.